Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Galanin receptor subtypes.

S Wang1, E L Gustafson

  • 1Department of CNS/CV Biological Research, Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.

Drug News & Perspectives
|December 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-α-induced depression in patients with chronic hepatitis C.

Molecular psychiatry·2011
Same author

Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice.

The Journal of endocrinology·2005
Same author

Cloning and characterization of a novel human histamine receptor.

The Journal of pharmacology and experimental therapeutics·2001
Same author

Identification of a novel neuromedin U receptor subtype expressed in the central nervous system.

The Journal of biological chemistry·2000
Same author

Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U.

Molecular pharmacology·2000
Same author

Expression of a novel neuropeptide Y receptor subtype involved in food intake: an in situ hybridization study of Y5 mRNA distribution in rat brain.

Experimental neurology·2000
Same journal

New drug discovery and development in India.

Drug news & perspectives·2013
Same journal

Are we living in the end of the blockbuster drug era?

Drug news & perspectives·2010
Same journal

Molecule of the Month. TAK-875.

Drug news & perspectives·2010
Same journal

Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.

Drug news & perspectives·2010
Same journal

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Drug news & perspectives·2010
Same journal

Trioxaquines: hybrid molecules for the treatment of malaria.

Drug news & perspectives·2010
See all related articles

Galanin receptors are key targets for drug development, with three subtypes (GalR1, GalR2, GalR3) now cloned. This cloning facilitates the discovery of selective drugs for conditions like obesity and pain.

Area of Science:

  • Pharmacology
  • Neuroscience
  • Endocrinology

Background:

  • Galanin receptors are significant targets for pharmaceutical research due to their role in various therapeutic areas.
  • Galanin is found in both central nervous system and peripheral tissues, including the gastrointestinal tract, pancreas, bladder, and genital tract.
  • Galanin binding sites are prevalent in numerous brain regions.

Purpose of the Study:

  • To review the identification and characterization of galanin receptors.
  • To highlight the cloning of three galanin receptor subtypes (GalR1, GalR2, GalR3).
  • To emphasize the potential of cloned subtypes for drug discovery and therapeutic target association.

Main Methods:

  • Radioligand binding studies were used to identify and characterize galanin receptors.

Related Experiment Videos

  • Pharmacological data indicated the existence of multiple galanin receptor subtypes.
  • Molecular cloning of three galanin receptor subtypes (GalR1, GalR2, GalR3) has been achieved.

    • Main Results:

    • Galanin receptors were identified and characterized as glycoproteins (54-60 kDa).
    • Evidence supported multiple galanin receptor subtypes, with at least four distinguishable by pharmacology.
    • Three subtypes, GalR1, GalR2, and GalR3, have been successfully cloned.

    Conclusions:

    • Cloned galanin receptor subtypes enable high-throughput screening for potent and selective compounds.
    • These selective compounds will serve as crucial tools for studying galanin and its receptor functions, structures, and regulation.
    • Future research will focus on linking therapeutic targets like obesity, nociception, and mnemonic processes to specific GalR subtypes and developing novel, selective GalR modulators.